rs1800788 — FGB -854G>A

Upstream promoter variant in fibrinogen beta chain that increases IL-6-driven FGB transcription, raising plasma fibrinogen levels and amplifying cardiovascular and thrombotic risk

See your personal result for FGB

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The Fibrinogen Amplifier — How a Promoter Variant at -854 Raises the Clotting Threshold

Plasma fibrinogen is both the raw material for blood clots and a sensitive index of systemic inflammation. Every 1 g/L increase in fibrinogen11 Every 1 g/L increase in fibrinogen
Fibrinogen is synthesized in the liver and circulates at 2-4 g/L; levels rise during the acute-phase response to infection, surgery, or chronic low-grade inflammation doubles the hazard for coronary heart disease and nearly doubles it for ischemic stroke across 154,211 participants in the Fibrinogen Studies Collaboration. The rs1800788 variant — a G-to-A substitution 854 base pairs upstream of the FGB transcription start site, appearing as C>T on the genomic plus strand — sits within one of the three truly functional regulatory nodes of the beta-fibrinogen promoter. The T allele at this position (corresponding to the -854A allele in older literature) increases transcriptional output, raising the constitutive fibrinogen set point and amplifying the inflammatory surge when IL-6 signaling rises.

The Mechanism

The FGB gene on chromosome 4q31 encodes the beta chain of fibrinogen. Its promoter region contains multiple binding sites for transcription factors activated by interleukin-6 (IL-6)22 interleukin-6 (IL-6)
The primary hepatic acute-phase cytokine; released during infection, surgery, metabolic stress, or chronic inflammation; directly drives FGB transcription in hepatocytes, the master cytokine that signals the liver to ramp up acute-phase protein production.

Transfection studies in HepG2 liver cells by van 't Hooft et al. 199933 van 't Hooft et al. 1999
Van 't Hooft FM et al. Two common, functional polymorphisms in the promoter region of the beta-fibrinogen gene contribute to regulation of plasma fibrinogen concentration. Arterioscler Thromb Vasc Biol. 1999;19(12):3063-70 demonstrated that the -854A allele (T on the plus strand) increases basal transcription by approximately 51% compared to the reference G allele. This is not a passive association — the polymorphism alters the binding landscape for nuclear regulatory proteins at this locus, directly changing how strongly the gene is expressed in liver cells.

Further confirmation of functional status came from Morozumi et al. 200944 Morozumi et al. 2009
Morozumi T et al. The functional effects of the -455G/A polymorphism on the IL-6-induced expression of the beta-fibrinogen gene may be due to linkage disequilibrium with other functional polymorphisms. Immunol Invest. 2009;38(3-4):311-23, who used artificial haplotype constructs to isolate individual site effects. Among three candidate functional polymorphisms (-1420G/A, -854G/A, and -148C/T), the -854A allele significantly raised IL-6-induced promoter activity. This places rs1800788 in a select group of FGB promoter variants with direct experimental evidence of functional consequence, distinct from -455G/A, whose effects may be largely mediated through linkage disequilibrium with these truly functional sites.

The Evidence

The in vitro transcription data are compelling: the -854A allele raises basal FGB promoter output by ~51%. Van 't Hooft et al. showed that plasma fibrinogen levels in healthy middle-aged men were significantly higher in carriers of the rare alleles at both -455G/A and -854G/A, with the two polymorphisms together explaining approximately 11% of plasma fibrinogen variation — a substantial fraction given the many environmental contributors.

Population-level haplotype evidence comes from the HIFMECH study55 HIFMECH study
Mannila MN et al. Plasma fibrinogen concentration predicts the risk of myocardial infarction differently in various parts of Europe. J Intern Med. 2005;257(3):247-57, a four-centre European case-control investigation. The -854G/A site was included in the haplotype analysis alongside -249C/T and -455G/A. The FGB promoter haplotype block significantly predicted fibrinogen concentration in MI patients (p<0.001, explaining 11.5% of fibrinogen variance); elevated fibrinogen was an independent predictor of MI only in the London cohort (standardized OR=3.58, 95% CI 1.31-9.83), with geographic and environmental modifiers shaping when genetically elevated fibrinogen translates into measurable clinical risk.

The overall fibrinogen-cardiovascular disease relationship provides the quantitative context: the Fibrinogen Studies Collaboration66 the Fibrinogen Studies Collaboration
Fibrinogen Studies Collaboration. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality. JAMA. 2005;294(14):1799-809 established hazard ratios of 2.42 per 1 g/L increase for CHD and 2.06 per 1 g/L for stroke, with no threshold — even modest constitutive elevations accumulate risk continuously. When the -854A allele contributes to a persistently higher fibrinogen baseline, each inflammatory episode can push levels into ranges that appreciably increase event probability.

One note on evidence interpretation: an exercise study in 762 male army recruits found no independent effect of -854G/A on exercise-induced fibrinogen elevation after controlling for -455G/A genotype, suggesting the in vivo fibrinogen signal is dominated by the LD haplotype block. The individual contribution of rs1800788 to circulating fibrinogen may therefore be smaller than the in vitro data suggests, and is best understood as part of the FGB promoter haplotype rather than as a fully isolated effect.

Practical Actions

The T allele raises FGB promoter activity at baseline and under IL-6 stimulation. For carriers, the most actionable implication is that plasma fibrinogen should be measured as part of cardiovascular risk profiling — not as a diagnosis, but to determine whether the genetic upregulation has translated into measurable elevation. If fibrinogen is elevated (>3.5-4 g/L), targeted interventions can reduce it: long-chain omega-3 fatty acids (EPA+DHA) lower fibrinogen by 0.2-0.5 g/L in controlled trials — one of the few interventions with documented fibrinogen-lowering efficacy of clinical magnitude.

Tobacco is the strongest environmental amplifier of the FGB promoter: smoking raises fibrinogen by 0.5-1.0 g/L independently, compounding any genetic elevation and dramatically expanding the range of inflammatory insult.

Interactions

rs1800788 sits in a haplotype block with the other major FGB promoter variants: rs1800790 (-455G>A) and rs1800787 (-148C>T). Importantly, the -854G/A site is in negative linkage disequilibrium with -455G/A and -148C/T in Chinese Han populations, meaning the fibrinogen-raising alleles at these sites do not co-occur as frequently as might be expected — the haplotype structure partially distributes risk across these positions. The HIFMECH data identified four major European haplotypes (CGG ~47%, CAG ~20%, TGG ~18%, CGA ~15%), with distinct fibrinogen effects per haplotype. Individuals carrying the -854A (T) allele alongside the -455A or -148T alleles warrant the most aggressive monitoring, as combined haplotype burden on FGB transcription is likely additive. See rs1800790 (-455G>A) and rs1800787 (-148C>T) for the complementary variant profiles.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal FGB Promoter Normal

Common C/C genotype — no promoter-driven elevation of fibrinogen from this site

You carry two copies of the C allele at rs1800788 (FGB -854), the reference genotype found in approximately 64% of people globally. The -854 site does not activate additional FGB transcription in your case, and your fibrinogen level is not elevated through this regulatory pathway. Fibrinogen is still influenced by inflammation, metabolic health, smoking, and other genetic variants — but this promoter position adds no extra upward pressure on your constitutive set point.

CT Elevated FGB Promoter Activity Intermediate

One T allele — mildly increased FGB promoter activity and modestly elevated fibrinogen baseline

The clinical relevance of mildly elevated fibrinogen depends on your overall cardiovascular risk profile. The Fibrinogen Studies Collaboration established a continuous dose-response: each 1 g/L increase in fibrinogen carries a hazard ratio of 2.42 for CHD and 2.06 for stroke. Constitutively higher set points — even by fractions of a gram — mean that any acute inflammatory challenge (infection, surgery, dental disease, metabolic stress) starts from an already-elevated baseline and reaches higher peak values.

The -854 site is in the same haplotype block as rs1800790 (-455G/A) and rs1800787 (-148C/T). Carriers of risk alleles at multiple FGB promoter positions experience additive transcriptional burden, and their absolute fibrinogen elevation will be larger than from any single variant alone.

TT High FGB Promoter Activity High Risk

Two T alleles — constitutively elevated FGB transcription with substantially higher fibrinogen baseline

The functional significance of homozygous -854A status lies in two compounding mechanisms. First, basal fibrinogen production is higher at steady state — each copy of the T allele independently upregulates FGB transcription. Second, under acute-phase stimulation (IL-6 signaling during infection, surgery, or inflammatory flares), the promoter is already primed for amplified output. The HIFMECH European multi-centre study found that the FGB haplotype block explains 11.5% of fibrinogen variance in MI patients and that elevated fibrinogen predicted MI risk independently of traditional risk factors (OR=3.58 in the London cohort). When the -854 locus is fully activated by TT genotype, the total haplotype contribution to fibrinogen elevation is at its maximum from this site.

The Fibrinogen Studies Collaboration (154,211 participants) established that there is no safe threshold: each 1 g/L increment in fibrinogen adds proportional cardiovascular risk (CHD HR=2.42, stroke HR=2.06). Constitutively higher baseline means less additional insult is needed to cross the ranges where thrombotic events become substantially more likely. Active monitoring and fibrinogen-lowering interventions are warranted before a clinical event, not in response to one.